Washington State Prescription Drug Transparency Reporting: Manufacturers

Having trouble viewing this email? View it as a Web page.

Health Care Authority (HCA) logo

Washington State Prescription Drug Transparency Reporting: Manufacturers

The Health Care Authority (HCA) is writing you to pass along important information pertaining to your role in the prescription drug price transparency program, and to extend our sincere thanks to those who participated in our listening sessions. Your feedback and voice is critical to building a functioning and reasonable reporting program.

Why am I receiving this?

The Washington State Prescription Drug Transparency Reporting program requires reporting from carriers, pharmacy benefit managers, drug manufacturers, and pharmacy service administrative organizations.

You are receiving this because either:

  • We have identified your organization as a required drug manufacturer data submitter under this legislative mandate, or,
  • You signed up for manufacturer updates on the drug price transparency website. If you are not the representative of a required submitter please:
    • Click unsubscribe at the bottom of this alert. You will be removed from this targeted distribution list, but will still receive general information updates.
    • Disregard the rest of this notification.

If you believe you have received this notification in error, and you are exempt from reporting, please email HCA.

What do I need to do?

  • Please confirm that you are the correct recipient of these notifications by registering as a data submitter. If you are not the correct contact in your organization, please forward this to the responsible person so they may register.
  • Download, complete, and return the submitter registration form.
  • Please do this as soon as possible but no later than August 1, 2020 as failure to submit registration information could delay your ability to be in compliance with the new legislation.

What can I expect next?

HCA is working on the specific data elements needed, and will provide a draft of the data definitions for your review and comment. Our intention is to have those sent mid-May.

You will receive a series of letters from us identifying next steps and delivering tools such as:

  • Data definitions
  • Data submission guide
  • Data submittal instructions

Questions?

HCA has created a drug price transparency webpage where you can stay connected with recent updates and contact us.